Mirum Pharmaceuticals reports Q2 EPS (52c), consensus (47c)

Reports Q2 revenue $77.8M, consensus $75.25M. As of June 30, 2024, Mirum had cash, cash equivalents and investments of $295.4M compared to $286.3M as of December 31, 2023. The company said, “”The second quarter was marked by significant achievements across both our commercial medicines and development pipeline as we continued to execute on our strategic priorities. The positive interim results of volixibat in the VISTAS PSC and VANTAGE PBC studies are exciting steps towards potential new treatment options for patients suffering from these rare liver diseases. We also achieved key regulatory milestones expanding access to LIVMARLI for patients with PFIC beginning with an approval in Europe for patients three months and older and a label expansion in the US to include patients 12 months and older, and we filed a new drug application for chenodiol in CTX. Finally, we are exploring LIVMARLI’s potential to treat cholestatic pruritus in other indications with the initiation of the EXPAND study.”